top of page
Novartis Invests Heavily Against Inflammation in Heart Disease
Novartis acquires Tourmaline Bio for $1.4 billion, focusing on pacibekitug, a drug that combats inflammation in heart disease like ASCVD, promising significant advancements in cardiovascular treatment.
- CommentsShare Your ThoughtsBe the first to write a comment.
bottom of page